ProCE Banner Activity

KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC

Slideset Download
Conference Coverage
Pembrolizumab monotherapy was well tolerated and active in a subset of pretreated metastatic TNBC patients, with promising preliminary survival results observed in patients with CR, PR, or SD.

Released: June 04, 2017

Expiration: June 03, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology